In the past week, ROIV stock has gone down by -2.08%, with a monthly gain of 3.91% and a quarterly surge of 0.25%. The volatility ratio for the week is 2.58%, and the volatility levels for the last 30 days are 2.99% for Roivant Sciences Ltd The simple moving average for the last 20 days is 1.63% for ROIV stock, with a simple moving average of 8.33% for the last 200 days.
Is It Worth Investing in Roivant Sciences Ltd (NASDAQ: ROIV) Right Now?
The price-to-earnings ratio for Roivant Sciences Ltd (NASDAQ: ROIV) is above average at 2.16x. The 36-month beta value for ROIV is also noteworthy at 1.26. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ROIV is 380.88M, and at present, short sellers hold a 11.38% of that float. The average trading volume of ROIV on December 10, 2024 was 6.25M shares.
ROIV) stock’s latest price update
Roivant Sciences Ltd (NASDAQ: ROIV)’s stock price has plunge by -1.13relation to previous closing price of 12.36. Nevertheless, the company has seen a -2.08% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-04 that Roivant Sciences leverages its “Vant” model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat position Roivant for significant clinical and commercial milestones by 2025. Strategic divestitures, like Dermavant’s sale to Organon for $1.2 billion, support shareholder value through share buybacks and bolster financial stability.
Analysts’ Opinion of ROIV
Many brokerage firms have already submitted their reports for ROIV stocks, with Wolfe Research repeating the rating for ROIV by listing it as a “Outperform.” The predicted price for ROIV in the upcoming period, according to Wolfe Research is $17 based on the research report published on February 15, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ROIV reach a price target of $20. The rating they have provided for ROIV stocks is “Overweight” according to the report published on January 05th, 2024.
Deutsche Bank gave a rating of “Buy” to ROIV, setting the target price at $14 in the report published on December 12th of the previous year.
ROIV Trading at 3.52% from the 50-Day Moving Average
After a stumble in the market that brought ROIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.40% of loss for the given period.
Volatility was left at 2.99%, however, over the last 30 days, the volatility rate increased by 2.58%, as shares surge +2.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.45% upper at present.
During the last 5 trading sessions, ROIV fell by -2.08%, which changed the moving average for the period of 200-days by +5.34% in comparison to the 20-day moving average, which settled at $12.02. In addition, Roivant Sciences Ltd saw 8.82% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ROIV starting from Venker Eric, who sale 100,000 shares at the price of $11.32 back on Nov 20 ’24. After this action, Venker Eric now owns 606,525 shares of Roivant Sciences Ltd, valued at $1,132,000 using the latest closing price.
Venker Eric, the Officer of Roivant Sciences Ltd, proposed sale 100,000 shares at $11.32 during a trade that took place back on Nov 20 ’24, which means that Venker Eric is holding shares at $1,132,008 based on the most recent closing price.
Stock Fundamentals for ROIV
Current profitability levels for the company are sitting at:
- 34.48 for the present operating margin
- 0.89 for the gross margin
The net margin for Roivant Sciences Ltd stands at 38.27. The total capital return value is set at 0.77. Equity return is now at value 159.08, with 117.35 for asset returns.
Currently, EBITDA for the company is 4.31 billion with net debt to EBITDA at -0.44. When we switch over and look at the enterprise to sales, we see a ratio of 55.53. The receivables turnover for the company is 5.54for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.43.
Conclusion
In summary, Roivant Sciences Ltd (ROIV) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
